BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26925628)

  • 21. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
    Tseng JH; Chen CY; Chen PC; Hsiao SH; Fan CC; Liang YC; Chen CP
    Oncotarget; 2017 Feb; 8(9):14666-14679. PubMed ID: 28108734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
    Garcia CG; Kahn SA; Geraldo LHM; Romano I; Domith I; Silva DCLE; Dos Santos Assunção F; Ferreira MJ; Portugal CC; de Souza JM; Romão LF; Netto ADP; Lima FRS; Cossenza M
    Mol Neurobiol; 2018 Aug; 55(8):6816-6833. PubMed ID: 29349577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma.
    Baritchii A; Jurj A; Soritau O; Tomuleasa C; Raduly L; Zanoaga O; Cernea D; Braicu C; Neagoe I; Stefan Florian I
    J BUON; 2016; 21(1):199-207. PubMed ID: 27061549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
    Degorre C; Tofilon P; Camphausen K; Mathen P
    Radiat Oncol; 2021 Sep; 16(1):191. PubMed ID: 34583727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study.
    Lee PY; Wei YT; Chao KC; Chu CN; Chung WH; Wang TH
    J Cancer Res Ther; 2024 Apr; 20(2):555-562. PubMed ID: 38687925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How I treat glioblastoma in older patients.
    Mohile NA
    J Geriatr Oncol; 2016 Jan; 7(1):1-6. PubMed ID: 26725536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
    Lester A; Rapkins R; Nixdorf S; Khasraw M; McDonald K
    Clin Transl Oncol; 2017 Mar; 19(3):273-278. PubMed ID: 27655368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review.
    Yuan Y; Xiang W; Qing M; Yanhui L; Jiewen L; Yunhe M
    Seizure; 2014 Nov; 23(10):830-5. PubMed ID: 25066904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.
    Krauze AV; Mackey M; Rowe L; Chang MG; Holdford DJ; Cooley T; Shih J; Tofilon PJ; Camphausen K
    Neurooncol Pract; 2018 Nov; 5(4):246-250. PubMed ID: 30402263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
    Chang JE; Khuntia D; Robins HI; Mehta MP
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Directions in the Treatment of Glioblastoma.
    Reitman ZJ; Winkler F; Elia AEH
    Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
    Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
    J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
    J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.